PolyPeptide Group AG (PPGN)

Currency in CHF
37.30
+0.75(+2.05%)
Closed·
PPGN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
36.2037.30
52 wk Range
19.6241.70
Key Statistics
Bid/Ask
36.15 / 37.65
Prev. Close
36.55
Open
36.9
Day's Range
36.2-37.3
52 wk Range
19.62-41.7
Volume
35.36K
Average Volume (3m)
75.74K
1-Year Change
76.3593%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PPGN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
37.60
Upside
+0.79%
Members' Sentiments
Bearish
Bullish
ProTips
High return over the last year

PolyPeptide Group AG News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

5 Buy
0 Hold
1 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 37.60
(+0.79% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Barclays
Buy40.00+7.24%33.00MaintainJun 16, 2026
Berenberg
Buy38.00+1.88%35.00MaintainJun 16, 2026
UBS
Buy40.00+7.24%38.00MaintainApr 07, 2026
Berenberg
Buy35.00-6.17%30.00MaintainJan 22, 2026
UBS
Buy38.00+1.88%32.00MaintainJan 21, 2026

Earnings

Latest Release
Mar 12, 2026
EPS / Forecast
0.16 / --
Revenue / Forecast
222.23M / --
EPS Revisions
Last 90 days

PPGN Income Statement

Compare PPGN to Peers and Sector

Metrics to compare
PPGN
Peers
Sector
Relationship
P/E Ratio
−63.1x−4.0x−0.5x
PEG Ratio
7.600.050.00
Price/Book
3.9x1.6x2.6x
Price / LTM Sales
3.4x2.0x3.0x
Upside (Analyst Target)
6.9%24.1%58.6%
Fair Value Upside
Unlock22.9%10.2%Unlock

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, pharmaceutical, and biotech companies. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.

Employees
1440

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
4.89M14.81%178.63M
Other Institutional Investors
17.16M52.00%627.30M
Public Companies & Retail Investors
10.96M33.20%400.46M
Total
33.01M100.00%1.21B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Draupnir Holding B.V.56.30%18,582,406679,187
Premier Miton Investment Funds 3 - Premier Miton European Opportunities Fund4.34%1,433,47652,394

People Also Watch

67.00
BANB
-0.15%
96.0000
SIVEH
-5.79%
67.68
SDZ
-1.60%
699.60
PGHN
-1.99%
185.00
SPCX
-3.56%

FAQ

What Is the PolyPeptide Group AG (PPGN) Stock Price Today?

The PolyPeptide Group AG stock price today is 37.30 CHF.

What Stock Exchange Does PolyPeptide Group AG Trade On?

PolyPeptide Group AG is listed and trades on the Switzerland Stock Exchange.

What Is the Stock Symbol for PolyPeptide Group AG?

The stock symbol for PolyPeptide Group AG is "PPGN."

What Is the PolyPeptide Group AG Market Cap?

As of today, PolyPeptide Group AG market cap is 1.21B CHF.

What Is PolyPeptide Group AG's Earnings Per Share (TTM)?

The PolyPeptide Group AG EPS (TTM) is -0.64.

From a Technical Analysis Perspective, Is PPGN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has PolyPeptide Group AG Stock Split?

PolyPeptide Group AG has split 0 times.

How Many Employees Does PolyPeptide Group AG Have?

PolyPeptide Group AG has 1440 employees.

What is the current trading status of PolyPeptide Group AG (PPGN)?

As of Jun 18, 2026, PolyPeptide Group AG (PPGN) is trading at a price of 37.30 CHF, with a previous close of 36.55 CHF. The stock has fluctuated within a day range of 36.20 CHF to 37.30 CHF, while its 52-week range spans from 19.62 CHF to 41.70 CHF.

What Is PolyPeptide Group AG (PPGN) Price Target According to Analysts?

The average 12-month price target for PolyPeptide Group AG is 37.60 CHF, with a high estimate of 43.91680471 CHF and a low estimate of 25.48407878 CHF. 5 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +0.79% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.